Ondine Biomedical Advances Steriwave Commercialization

Ondine Biomedical Inc. has reported significant advancements in the commercialization of its Steriwave® nasal decolonization technology in Canada and the UK. This innovative 5-minute procedure aims to reduce healthcare-associated infections (HAIs) by rapidly decolonizing the nose without antibiotics or contributing to antimicrobial resistance (AMR).

In the UK, major NHS Trusts such as King's College Hospital and Leeds Teaching Hospitals are implementing Steriwave treatments before surgeries. Ondine has partnered with Mölnlycke Health Care to expand its reach to the UK, EU, and Middle East markets. In Canada, Steriwave is now standard in half of the country's top 10 hospitals, with more facilities adopting the technology for orthopedic surgeries.

Nicole Walby of Interior Health Authority highlighted Steriwave's acceptance among patients and its role in bolstering infection prevention protocols. Given the rise of AMR and its financial impact, Steriwave offers a promising solution without the risk of resistance.